We evaluated the use of topically administered betaxolol, a cardioselective beta-adrenergic
blocking agent, in 11 patients (eight women and three men, 40 to 81 years old) who had …

• Betaxolol, a new β 1-adrenergic blocker, was applied to 20 eyes of ten patients with ocular
hypertension. Topical 0.25% betaxolol was found to significantly lower intraocular pressure …

• Betaxolol hydrochloride (0.5%) and timolol maleate (0.5%) were compared in a six-month
randomized, double-blind study involving 29 patients with glaucoma. The two drugs were …

• Betaxolol hydrochloride, 0.5%, and timolol maleate, 0.5%, were compared in a 26-week
randomized, double-masked study involving 46 patients with primary open-angle glaucoma …

We evaluated the use of topically administered betaxolol 0.5% in 101 glaucoma patients (47
men and 54 women) who had chronic obstructive pulmonary disease, asthma, or timolol …

• The intraocular pressure response to topically instilled 0.25% betaxolol hydrochloride was
evaluated in 12 patients with chronic open angle glaucoma or ocular hypertension. The drug …

Synopsis Betaxolol is a lipophilic β-adrenoceptor antagonist relatively selective for β 1-
adrenoceptors with only weak β2-blocking activity. Used topically in glaucoma and ocular …

Objective: To study the cardiopulmonary safety and ocular hypotensive efficacy of topical
betaxolol hydrochloride 0.5%(a selective beta‐1 blocker) in patients with unacceptably …

We conducted a six-month prospective, double-masked randomized trial comparing
betaxolol with timolol at 0.25% and 0.5% concentrations in the treatment of primary open …

Timolol maleate, the first B-adrenergic antagonist available for the treatment of glaucoma
and ocular hypertension, was marketed in 1978 (1). Shortly after its introduction, systemic …